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OBJECTIVE — Traditional blood glucose–lowering agents do not sustain adequate glycemic
control in most type 2 diabetic patients. Preclinical studies with exenatide have suggested
sustained improvements in -cell function. We investigated the effects of 52 weeks of treatment
with exenatide or insulin glargine followed by an off-drug period on hyperglycemic clamp–
derived measures of -cell function, glycemic control, and body weight.
RESEARCH DESIGN AND METHODS — Sixty-nine metformin-treated patients with
type2diabeteswererandomlyassignedtoexenatide(n36)orinsulinglargine(n33).-Cell
function was measured during an arginine-stimulated hyperglycemic clamp at week 0, at week
52, and after a 4-week off-drug period. Additional end points included effects on glycemic
control, body weight, and safety.
RESULTS — Treatment-induced change in combined glucose- and arginine-stimulated
C-peptide secretion was 2.46-fold (95% CI 2.09–2.90, P  0.0001) greater after a 52-week
exenatide treatment compared with insulin glargine treatment. Both exenatide and insulin
glargine reduced A1C similarly: 0.8  0.1 and 0.7  0.2%, respectively (P  0.55).
Exenatide reduced body weight compared with insulin glargine (difference 4.6 kg, P 
0.0001). -Cell function measures returned to pretreatment values in both groups after a
4-week off-drug period. A1C and body weight rose to pretreatment values 12 weeks after
discontinuation of either exenatide or insulin glargine therapy.
CONCLUSIONS — Exenatidesigniﬁcantlyimproves-cellfunctionduring1yearoftreat-
ment compared with titrated insulin glargine. After cessation of both exenatide and insulin
glargine therapy, -cell function and glycemic control returned to pretreatment values,
suggesting that ongoing treatment is necessary to maintain the beneﬁcial effects of either
therapy.
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T
ype 2 diabetes is characterized by
-cell dysfunction against a back-
groundofobesity-relatedinsulinre-
sistance (1). When lifestyle measures and
oral blood glucose–lowering medications
fail to sustain glycemic control, current
guidelines advise the use of basal insulin
(2). Data from the U.K. Prospective Dia-
betes Study suggest that glycemic control
progressively worsens over time, and this
deteriorationhasbeenattributedtoapro-
gressivelossof-cellfunctionthatoccurs
irrespective of whether metformin, sulfo-
nylureas, or insulin are used (3). There-
fore, therapeutic approaches, which may
prevent or delay the decline of -cell
function in type 2 diabetes, are eagerly
awaited.
Exenatideissyntheticexendin-4,ﬁrst
identiﬁed and isolated from the salivary
secretions of the Gila monster (Heloderma
suspectum). Exendin-4 shares 53% amino
acid sequence identity with human gluca-
gon-likepeptide(GLP)-1andbindsdirectly
to GLP-1 receptors. Placebo-controlled
(4–7) and comparator-controlled (8–10)
clinical studies have demonstrated that
exenatide improves glycemic control and
reducesbodyweightinpatientswithtype
2 diabetes. These studies also showed
ameliorationofsurrogatemeasuresof-cell
function (4–6,8). Accordingly, improve-
ments have been demonstrated in ﬁrst- and
second-phase glucose-stimulated insulin
secretion and in meal-derived indexes of
-functioncomparedwithplacebo(11,12).
In animals, exenatide has been shown to
sustain improvements in -cell function or
even increase -cell mass (13).
Previously, we showed that 26-week
exenatide therapy lowered A1C similarly
to insulin glargine in patients with type 2
diabetes who were treated with met-
formin and a sulfonylurea (8). However,
at present, no data exist regarding the rel-
ative effects of these treatments on -cell
function, nor is it known whether the ef-
fects of either therapy are sustained after
discontinuation. The aim of the current
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with exenatide or insulin glargine on
-cell function, glycemic control, body
weight, and safety, after 52 weeks of
treatment and during a 12-week off-
drug period.
RESEARCH DESIGN AND
METHODS— The study was per-
formed between 27 September 2004 and
13September2007atthreestudysites,in
Sweden,Finland,andtheNetherlands.In
total, 69 patients were randomly assigned
using a permutated block randomization
scheme stratiﬁed by site and screening
A1C to receive exenatide or insulin
glargine, in addition to ongoing met-
formin treatment (Fig. 1). Inclusion crite-
ria were age 30–75 years, A1C 6.5–9.5%,
BMI 25–40 kg/m
2, and metformin treat-
mentatastabledoseforatleast2months.
No other blood glucose–lowering agents
were allowed within 3 months before
screening. No changes in other agents
known to affect -cell function (such as
ACE inhibitors and angiotensin receptor
blockers) were allowed during the study.
The study protocol was approved by the
ethics review committee at each site and
was in accordance with the principles de-
scribed in the Declaration of Helsinki. All
participating patients gave their written
informed consent before screening.
Patients randomly assigned to ex-
enatide (n  36) initiated treatment at a
doseof5gb.i.d.,injected15minbefore
breakfast and dinner, for a period of 4
weeks, followed by a dose increase to 10
g b.i.d. Exenatide was titrated to a max-
imum dose of 20 g t.i.d., or the maxi-
mum tolerated dose, when A1C ranged
from7.1to7.5%attwoconsecutivevisits
or when A1C was 7.6% at any given
visit. Patients randomly assigned to insu-
lin glargine (n  33) started at an initial
dose of 10 IU q.d., injected at bedtime.
Patients were instructed to increase the
daily dose based on their fasting self-
monitored blood glucose (SMBG) levels,
according to a prespeciﬁed algorithm
(14). When fasting SMBG was 5.6
mmol/l on 3 consecutive days, the insulin
dose was increased by 2 units until ﬁnally
fasting SMBG would range between 4.5
and 5.5 mmol/l. If a hypoglycemic event
(3.3 mmol/l) occurred, patients were
instructed to refrain from increasing the
insulin glargine dose for 7 days and to
contact the study physician. When neces-
sary, the importance of proper titration of
insulin was emphasized.
Study end points
Insulin secretion and sensitivity were
measured during a combined euglycemic-
hyperinsulinemic and hyperglycemic
clamp procedure (supplementary Fig. 1A,
available in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc08-1797/DC1) (15,16). First- and
second-phase C-peptide secretion was
calculated as area under the curve
(AUC)180–190 min and AUC190–260 min.
Arginine-stimulated C-peptide secretion
(AIRarg)wascalculatedastheincremental
AUC260–270 min above the fasting C-pep-
tide concentration. Arginine was admin-
istered during a hyperglycemic clamp to
measure maximum insulin secretory ca-
pacityatasteady-stateglucoseconcentra-
tion of 15 mmol/l (17). Clamps were
performedbeforerandomization,after52
weeks of treatment, and after a 4-week
off-drug period. After an overnight fast,
an indwelling cannula was inserted into
anantecubitalveinforinfusionofglucose
andinsulin.Toobtainarterializedvenous
bloodsamples,ancannulawasinsertedin
a retrograde fashion into a dorsal hand or
wristveinandmaintainedinaheatedbox
at 50°C. During the clamp at week 52,
patients randomly assigned to exenatide,
were given the study drug 15 min before
the onset of the hyperglycemic clamp,
andpatientsrandomlyassignedtoinsulin
glargine received their last insulin dose
the night before at bedtime.
A1C (normal range: 4.3–6.1%, Dia-
betes Control and Complications Trial
standardized Bio-Rad assay) was mea-
sured using the fasting plasma glucose,
and safety parameters were measured be-
fore randomization and during each fol-
low-up visit until the end of the 12-week
off-drug period by a central laboratory
(Quintiles, Livingston, U.K.). Patients
were instructed to record seven-point
(fasting, 2 h after breakfast, before lunch,
2 h after lunch, before dinner, 2 h after
dinner, and at bedtime) SMBG proﬁles
using an OneTouch Ultra blood glucose
meter (LifeScan, Milpitas, CA) before
each visit. Plasma glucose concentrations
duringtheclampweremeasuredusingan
YSI2300STATPlusanalyzer(YSI,Yellow
Springs, OH) in Sweden and the Nether-
lands and using a Beckman Coulter Glu-
cose Analyzer II (Beckman Coulter,
Fullerton, CA) in Finland. C-peptide sam-
ples were analyzed at the VU University
MedicalCenterusinganimmunoradiomet-
ric assay (Centaur; Bayer Diagnostics, Mij-
drecht, Netherlands).
Statistical analysis
The primary efﬁcacy end point of this
study is the treatment effect on -cell
function as measured by the ratio of week
52 combined glucose- and arginine-
stimulated insulin secretion during a hy-
perglycemic clamp. A sample size of 26
patients per group was required to pro-
vide 90% power to detect a between-
group signiﬁcant difference in arginine-
stimulated insulin secretion between the
two treatment groups, assuming that the
mean incremental AUC value at baseline is
200pmol min
1 l
1forbothgroupsand
values at week 52 are 1,100 and 300 pmol 
min
1   l
1 for the exenatide and insulin
glargine groups, respectively (11,18).
All outcome measures were com-
pared between the two treatment groups
using an ANCOVA model. The depen-
dent variable used in the model is the
loge-transformedratiotopretreatmentfor
the -cell function parameters (AIRarg,
ﬁrst phase, and second phase). For all
other end points the dependent value
used is the mean at the corresponding
visit. The model includes factors for treat-
ment group (exenatide/glargine), site
(Netherlands/Sweden/Finland), and base-
line A1C stratum (8.5%/8.5%), and
the pretreatment variable of the corre-
spondingdependentvariableasacovariate.
Statistical analysis was done using
SAS software (SAS Institute, Cary, NC).
All inferential statistical tests were con-
ductedatasigniﬁcancelevelof0.05(two-
sided). Unless otherwise stated, data are
presented as means  SEM.
RESULTS
Patient disposition and baseline
clinical characteristics
Patient disposition and baseline clinical
characteristics are shown in Fig. 1. Sixty
patients completed the 52-week treat-
mentperiod.Ofthepatientsrandomlyas-
signed to exenatide, 62.1% (n  18) were
treated with exenatide 10 g b.i.d. at 52
weeksoftreatment.Five(17.2%)patients
were using 20 g t.i.d., two (6.9%) were
using 10 g t.i.d., one (3.4%) was using
15gb.i.d.,andone(3.4%)wasusing15
g of t.i.d. The daily exenatide dose was
reduced to 5 g b.i.d. in two patients
(6.9%). Despite this increase in daily ex-
enatidedose,noneofthesepatientsreached
the A1C target of 7.1%. At 52 weeks, the
mean  SEM insulin glargine dose used
was 33.6 3.5 units/day. The correspond-
ing fasting SMBG in the insulin glargine–
treated group was 5.6  0.2 mmol/l.
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Exenatide and insulin glargine treatment
resulted in similar reductions in A1C
(0.8  0.1 and 0.7  0.2%, respectively;
P  0.55), with both groups achieving a
mean A1C of 6.8% at 52 weeks. The in-
sulin glargine group showed a signiﬁ-
cantly greater reduction in fasting plasma
glucose compared with the exenatide
group (2.9  0.4 vs. 1.6  0.3
mmol/l, respectively; P  0.0001),
whereasSMBGproﬁlesdemonstratedsig-
niﬁcantly greater reductions in postpran-
dial glucose excursions in the exenatide-
treated patients (Fig. 2C and D). During
the off-drug period, both A1C and fasting
plasma glucose increased in both groups
and were not signiﬁcantly different com-
pared with pretreatment values after 12
weeks off-drug (Fig. 2A and B).
Body weight and insulin sensitivity
Fifty-two weeks of exenatide treatment
resulted in a lowering of body weight of
3.6  0.6 kg, whereas treatment with
insulin glargine resulted in a body weight
increase of 1.0  0.8 kg (between-
group difference, 4.6  1.1 kg; P 
0.0001) (Fig. 2E). During the 12-week
off-drug period, body weight trended to-
ward baseline values with both therapies
(between-group difference 2.4  1.1
kg; P  0.03).
At baseline, insulin-mediated glucose
uptake did not differ between the two
treatment groups (Fig. 2F). Treatment
with exenatide and insulin glargine im-
proved insulin sensitivity to the same ex-
tent by 0.9  0.3 and 1.1  0.3 mg  
min
1   kg
1, respectively (P  0.49).
After a 4-week discontinuation of study
medication, the M value was not signiﬁ-
Figure 1—Protocol ﬂow chart and baseline characteristics of the study population. Data represent means  SEM.
Exenatide and -cell function
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in the insulin glargine–treated group,
whereas it remained signiﬁcantly higher
in the exenatide-treated group (between-
group difference 0.8  0.4 mg/min/kg;
P  0.03).
Hyperglycemic clamp–derived
measures of -cell function
At baseline, both glucose- and arginine-
stimulated C-peptide secretion did not
differbetweenthetwotreatmentgroups
(Table 1; Fig. 3A–D). After 52 weeks of
treatment, the exenatide group demon-
strated a signiﬁcant increase in all mea-
sures of -cell function. Accordingly,
exenatide treatment signiﬁcantly in-
creased ﬁrst- and second-phase glu-
cose-stimulated C-peptide secretion by
1.53  0.11- and 2.85  0.22-fold, re-
spectively(P  0.0001),comparedwith
insulin glargine. The C-peptide re-
sponse to arginine during hyperglyce-
mia increased 3.19  0.24-fold from
pretreatment in the exenatide group
compared with a 1.31  0.07-fold
increase in the insulin glargine group
(between-group difference 2.46 
0.20-fold; P  0.0001). After 4 weeks
discontinuation of the study medica-
tion, measures of -cell function re-
turned to pretreatment values in both
groups.
Figure2—TimecourseforA1C(A)andfastingplasmaglucose(B).SMBGconcentrationsbefore(C)andafter(D)52weeksoftreatment.Changes
in body weight (E) and insulin sensitivity were measured as the M value (F). Data are means  SEM. F, exenatide; E, insulin glargine; f,
pretreatment;  , 52 weeks on-drug; o, 4 weeks off-drug. Vertical black line at 52 weeks represents cessation of study medication. BB, before
breakfast; AB, after breakfast; BL, before lunch; AL, after lunch; BD, before dinner; AD, after dinner; BT, bedtime.
Bunck and Associates
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The most frequently observed adverse
event in exenatide-treated patients was
mild-to-moderate nausea (50%). Other
gastrointestinal adverse events were re-
ported more commonly in exenatide-
treated patients, including vomiting,
diarrhea, and abdominal distension. Bio-
chemically conﬁrmed hypoglycemia
Table 1—Measures of -cell secretory function during hyperglycemic clamp and ratio to pretreatment in the exenatide- and insulin
glargine–treated groups
Pretreatment
(week 2)
On-drug
(week 52)
Off-drug
(week 56)
On-drug ratio to pretreatment
(week 52)
Off-drug ratio to pretreatment
(week 56)
Geometric
mean
Between-group
difference P
Geometric
mean
Between-group
difference P
First phase
Insulin glargine 5.4  0.6 6.1  0.5 6.1  0.6 1.17  0.06 1.13  0.05
Exenatide 5.4  0.6 9.4  1.0 5.0  0.6 1.78  0.11 1.53  0.11 0.0001 1.00  0.05 0.90  0.06 0.1188
Second phase
Insulin glargine 77.4  8.8 80.7  6.9 86.2  9.1 1.08  0.05 1.10  0.05
Exenatide 78.5  8.3 235.6  23.0 79.5  9.1 3.05  0.22 2.85  0.22 0.0001 1.01  0.04 0.92  0.06 0.1996
AIRarg
Insulin glargine 20.0  2.5 24.8  2.2 21.4  2.5 1.31  0.07 1.03  0.08
Exenatide 19.7  2.1 62.2  7.0 22.0  2.6 3.19  0.24 2.46  0.20 0.0001 1.12  0.06 1.08  0.10 0.4052
Data represent mean  SEM. n  30 in the exenatide- and insulin glargine–treated groups. Ratios from pretreatment are presented as geometric mean  SEM.
AIRarg,C-peptideresponsetoarginineat15mmol/lglucoseconcentration(nmol min
1 l
1);ﬁrst-phase,ﬁrst-phaseC-peptideresponsetoglucose(nmol min
1
 l
1;second-phase,second-phaseC-peptideresponsetoglucose(nmol min
1 l
1).See RESEARCH DESIGN AND METHODSforcalculationsof-cellfunctionmeasures.
Figure 3—C-peptide concentrations during hyperglycemic clamp and ratio to pretreatment in the exenatide (A and C)- and insulin glargine (B and
D)-treated group. Data represent mean  SEM in A and B and geometric mean  SEM in C and D. AIRarg, C-peptide response to arginine at 15
mmol/l glucose concentration; 1st phase, ﬁrst-phase C-peptide response to glucose; 2nd phase, second-phase C-peptide response to glucose. See
RESEARCH DESIGN AND METHODS for calculations of -cell function measures. F, f, pretreatment; E, e, 52-weeks on-drug; f, o, 4 weeks off-drug.
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quently in the insulin glargine group
(24.2%) than in the exenatide-treated pa-
tients (8.3%). There was no severe hypo-
glycemia with either treatment. Other
adverse events observed more frequently
in the insulin glargine group included in-
ﬂuenza and gastroenteritis. One patient
randomly assigned to exenatide devel-
oped pancreatitis, which resolved after
withdrawal of the study medication.
CONCLUSIONS — This study dem-
onstrates that 52 weeks of treatment with
exenatide signiﬁcantly improves -cell
function compared with insulin glargine
in metformin-treated type 2 diabetic pa-
tients. In addition, exenatide treatment
achieved similar improvements in glyce-
mic control, reduced body weight, and
resulted in fewer hypoglycemic events.
Both exenatide and insulin glargine re-
sulted in similar improvements in whole-
body insulin sensitivity. After cessation of
both treatments, end point measures re-
turned to pretreatment values.
In type 2 diabetes, defects in -cell
function include an absent ﬁrst-phase in-
sulin response and a gradually diminish-
ingsecond-phaseresponsetoglucose(1).
This progressive loss of -cell function is
considered to be the main factor respon-
sible for the gradual increase of glycemia
over time, regardless of the therapy used
(3). Acute and chronic exposure to ex-
enatidehasbeenshowntoimprove-cell
function (4–6,8). However, there have
been no studies comparing -cell func-
tionafterlong-termexposuretoexenatide
or other glucose-lowering therapies. In
the current study, exenatide therapy for
1 year signiﬁcantly improved -cell
function compared with titrated insulin
glargine therapy, in the presence of
comparable improvements in glycemic
control.
A number of prior studies have dem-
onstrated that exenatide is not inferior to
insulin regimens as a glucose-lowering
treatment option in type 2 diabetic pa-
tients with inadequate glucose control
(8–10). These previous insulin compara-
tor trials have been criticized for not
achieving optimal insulin doses in the
comparator arm of the study (19) despite
mean reductions in A1C levels that were
within the range of reductions observed
in comparable insulin trials. In the cur-
rent study, insulin titration resulted in a
mean daily insulin dose of 34  19 units.
Although this insulin glargine dose is
lower than that used in other studies of
type 2 diabetes (20,21), SMBG targets
were achieved in the current study, sug-
gesting that insulin doses were appropri-
atelytitratedinthemajorityofpatients.In
addition, the intensive treatment with
both therapies reduced mean A1C values
after 52 weeks to 6.8%. In the LANMET
study (22), in which, comparable to our
study, insulin glargine was added to met-
forminmonotherapyinpatientswithtype
2 diabetes, a higher dose of insulin
glargine (68 units/day) was used. These
apparent differences in insulin glargine
dose may be attributed to the relatively
good baseline A1C in our population
compared with that of the LANMET par-
ticipants (A1C 9.5%).
One limitation of the current study
should be highlighted: exenatide was
given15minbeforethestartofthehyper-
glycemic clamp study. We therefore can-
not discriminate between acute and long-
term effects of exenatide on -cell
function. The current study does, how-
ever, support the observation that longer-
term treatment with exenatide does not
attenuate the known acute effects of this
therapyon-cellfunction,whereasactive
insulin therapy did not improve -cell
function to the same degree. Because the
primary study objective was to determine
the effects of both active exenatide and
insulin therapy on -cell function in type
2diabeticpatients,wedecidedtoperform
the tests on therapy, in accordance with
previous studies (18,23,24). These ﬁnd-
ings support the idea that longer-term ex-
enatidetreatmentcouldhaveanenduring
effect on -cell function.
In the current study, treatment with
both exenatide and insulin glargine re-
sulted in a similar reduction in A1C. Of
interest, the two therapies achieved this
result through different ways: exenatide
primarily affected postprandial glucose
excursions, with a modest effect on fast-
ing glucose, whereas insulin glargine pre-
dominantly reduced fasting plasma
glucose, without inﬂuencing postpran-
dial glucose elevations. The resultant av-
erage glucose concentrations are similar
in both treatment groups, as reﬂected by
the A1C concentration. Albeit modest,
the improved glycemic control in either
group may have lowered the hyperglyce-
mia-associated oxidative stress burden,
whichinpartmayexplainthemodestim-
provement in -cell function in the insu-
lin glargine group (25). Obviously,
patients treated with exenatide showed a
greaterimprovementinacute-cellfunc-
tion, which is considered to be the result
of binding to the -cell GLP-1 receptor
(13). These ﬁndings are consistent with
work in a number of animal models, in
which exenatide or GLP-1 has been
shown to increase -cell mass and to re-
duce apoptosis (13). Collectively, these
observationsleadtothequestionwhether
long-term exenatide administration to
patients with type 2 diabetes may restore
some of the -cell functionality that is
lost as part of the natural history of the
disease.
In our study the improved -cell func-
tion at 52 weeks was lost 4 weeks after ces-
sation of either study treatment, and this
was accompanied by an increase in plasma
glucose and A1C to pretreatment values in
both study arms. Interestingly, insulin sen-
sitivity remained signiﬁcantly improved af-
ter 4 weeks cessation of treatment in the
exenatide-treated group only. This ﬁnding
may suggest additional effects of exenatide,
possibly mediated by weight loss, which
maybeoflongerduration.Whetherlonger-
term exposure to exenatide can alter func-
tional -cell mass in the absence of active
exenatide treatment will require further
study. These effects may be dependent on
other factors including diabetes duration,
the amount of functional -cells present at
the initiation of therapy and overall meta-
bolic control achieved. To study a possible
preserving effect on -cell function, an ad-
ditional 2-year extension trial is currently
underway.
Both titrated exenatide and insulin
glargine were generally well tolerated
with 80% of patients in both groups
completing 1 year of therapy. These ther-
apeutic approaches differed in that the
most common side effects with exenatide
were of gastrointestinal origin, occurring
in a proportion of patients similar to that
reportedinpreviousstudies(4–10).Mild
to moderate nausea (47%) was the most
commonly reported adverse event with
exenatide. In contrast, hypoglycemia was
the most common adverse event reported
in 25% of the insulin glargine–treated
patients.
In summary, this study uniquely
demonstrates that 1 year of treatment
with exenatide signiﬁcantly improved
-cell function and reduced body weight
in the presence of similar improvements
in glycemic control compared with insu-
lin glargine treatment. After cessation of
therapy, the beneﬁcial effects on -cell
function, glycemic control, and body
weight were not sustained, suggesting
thatactivetreatmentisnecessarytomain-
tainthesebeneﬁcialeffectsofexenatidein
Bunck and Associates
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lowering therapy has failed.
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